Exagen Diagnostics, Inc. is a leader in the discovery and development of genomic marker tests that assist physicians with disease diagnosis, prognosis and treatment response. Exagen Discovers: Exagen’s proprietary computational engine, Coperna, enables us to discover accurate genomic marker sets across the spectrum of genomic data types, including the latest high density gene expression and SNP arrays. Other groups, using less powerful discovery techniques, will likely not identify marker sets approaching the performance of our Coperna-generated discoveries. Our superior ‘hit rate’ is a result of Coperna’s deeper search of genomic data for accurate marker sets, and following this, our validation that the identified marker sets are truly significant. The end result: high confidence that subsequent clinical studies will validate our computational discoveries. Exagen Develops: Even though the technology behind our discoveries may be ‘bleeding edge’, our marker sets can be implemented using technologies most appropriate for high volume clinical lab use. Marker sets of high potential clinical value can be developed into an assay suited for the intended application, whether that be disease diagnosis, prognosis, susceptibility, or prediction of likely treatment response. Exagen Delivers: Exagen is committed to translating our discovery and development into real solutions that are safe, reliable and cost effective.